|Bid||0.00 x 2900|
|Ask||0.00 x 1200|
|Day's range||35.47 - 37.89|
|52-week range||25.88 - 139.99|
|Beta (5Y monthly)||1.19|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||47.17|
SOUTH SAN FRANCISCO, Calif., May 18, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 2022 UBS Global Healthcare Conference on Monday, May 23 at 9:15 a.m. Eastern Time in New York.
●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6% increase as compared to the same period of 2021. Our N
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...